Please attach photo below:
Duke-NUS / SingHealth CV Template Updated as at 5 Sep 2016 Please do not delete any sections and use “NA” for no entry. Please use continuation pages when necessary.
(1) Personal Particulars Full Name (complete with degrees) : Last Name:
Richard Quek Hong Hui
Richard
NRIC Identity Card / Passport No.:
S7322124B
Date of Birth :
23 June 1973
Age :
Nationality :
Singaporean
Marital Status : Married
Gender :
42
Male / Female
Home Address :
931 Bukit Timah Road #04-22 Singapore 589643
Office Address :
11 Hospital Drive Singapore 169610
Tel No. :
6639 1450
Email :
(H)
(O) +65 6436 8000
(HP)
+65 9386 3702
[email protected]
(2) Brief Biography (1-2 paragraphs) Dr Richard Quek is the Deputy Head of Department, Medical Oncology, National Cancer Centre Singapore (NCCS). He is also the Program Director of the Medical Oncology Senior Residency Program charged with the development of the next generation of medical oncologists in his institution. His main clinical and research focus is in the area of sarcomas, gastrointestinal stromal tumors (GIST) and melanomas. As a key member of his institution’s sarcoma and melanoma multi-disciplinary care team, Dr Quek is heavily involved in the care and management of patients with sarcomas, GIST and melanomas. Dr Quek’s chief research interest is primarily focused on translational therapeutics, developing new molecularly targeted therapeutics in sarcoma and GIST in an academic environment. Having returned from a 2-year sarcoma fellowship at Dana-Farber/ Harvard Cancer Centre, Boston, USA, he is instrumental in leading the centre’s efforts in developing a large GIST and soft tissue/ bone sarcoma database, the first of its kind in Singapore, to study its unique disease patterns in our Asian patients. Dr Quek is also heavily involved in developing local, regional and international collaborations to improve clinical care and research for patients. Notably, he is the Principal Investigator of many clinical trials studying novel new drugs in the treatment of sarcoma, GIST and melanomas patients.
1 | Page
Curriculum Vitae of Richard Quek Hong Hui
(3) Current Appointment Details Institution of primary appointment: National Cancer Centre Singapore Secondary Appointment(s), if any (include clinical faculty appointment with NUS if applicable):
Adjunct Associate Professor Duke-NUS Graduate Medical School Singapore
Program Director, Medical Oncology Senior Residency
Present rank(s) and title(s): Deputy Head & Senior Consultant Adjunct Associate Professor Duke-NUS Graduate Medical School Singapore
(4) Educational & Training Qualifications Secondary School:
Institution Raffles Institution
Qualification obtained GCE “O” Level
Year 1989
Junior College:
Raffles Junior College
GCE “A” Level
1991
Basic Degree(s):
National University of Singapore
MBBS
1997
Post Basic Degree(s):
Royal College of Physicians (UK)
MRCP
2002
(5) Certification & Licensure (A) Medical Professional License Licensing Board National University of Singapore Ministry of Health Singapore Singapore Medical Council Academy of Medicine Singapore
2 | Page
Licence No.
Month / Year
MBBS
1997
Certificate of Specialist Accreditation Certificate of Specialist Registration (Medical Oncology) Fellow Academy of Medicine Singapore
2006 2006 2006
Curriculum Vitae of Richard Quek Hong Hui
(B) Specialty Certificate Certifying Board
Certificate No.
Month / Year
Singapore Medical Council
Jun 2006
(6) Membership in Professional & Academic Societies Organisation
Rank / Title/ Position
Chapter of Medical Oncology Singapore
Member
Month / Year 2015 - 2017
(7) Appointments & Positions (Employment History) Please list chronologically, beginning with first postgraduate position. Academic / Clinical : Date/ Period
Hospital / Institution
Rank /Title / Position
Jun 2006 – May 2008
National Cancer Centre Singapore Changi General Hospital National University of Singapore National Cancer Centre Singapore National Cancer Centre Singapore Duke-NUS Graduate Medical School Singapore
Associate Consultant
Date/ Period
Hospital / Institution
Rank /Title / Position
2011 – 2013
Chapter of Medical Oncologist, Academy of Medicine Singapore SingHealth Medical Oncology Residency National Cancer Centre Singapore
Honorary Secretary
Aug 2006 – Mar 2008 Jul 2007 – Jul 2009 Jun 2008 – May 2011 Jun 2011 – Present 1 Jul 2015 – Present
Visiting Specialist Clinical Teacher Consultant Senior Consultant Adjunct Associate Professor
Administrative :
1 Jul 2013 – Current 1 June 2013 - Current
3 | Page
Program Director Deputy Head of Department, Medical Oncology
Curriculum Vitae of Richard Quek Hong Hui
(8) Publications 1. R Quek, ST Lim, EH Tan. Pneumoperitoneum Following Percutaneous Lung Biopsy. Lancet. 2006;368:1794 2. R Quek, ST Lim, S Ong. Hepatocellular Carcinoma: Pathological Complete Response to Oral Capecitabine, Megestrol and Thalidomide. Acta Oncologica 2006;45;95-97. 3. R Quek, A Ty, ST Lim, SJ See, MC Wong, SP Yap, I Sng, SW Hee, M Tao. Primary Central Nervous System Lymphoma in an Asian Population: A 15-Year Experience. Onkologie 2006;29:455–459. 4. R Quek, WT Lim, KF Foo, WH Koo, A A-Manaf, HC Toh. Capecitabine and oxaliplatin (XELOX) is safe and effective in patients with advanced gastric cancer. Acta Oncologica 2007;46:1032-4. 5. ST Lim, F Gao, R Quek, LC Lim, LH Lee, SP Yap, S Loong, M Tao. The relationship of hepatitis B virus infection and non-Hodgkin’s Lymphoma and its impact on clinical characteristics and prognosis. European Journal of Haematology 2007;79:132-7. 6. JKC Yoong, LC Chew, R Quek, CH Lim, JQ Zai, KY Fong, J Thumboo. Cardiac lymphoma in primary Sjogren’s syndrome: A novel case established by targeted imaging and pericardial window. Journal of Thoracic and Cardiovascular Surgery 2007;134:513-14. 7. ST Lim, SW Hee, R Quek, LC Lim, SP Yap, S Loong, I Sng, LHC Tan, MK Ang, J Ngeow, CK Tham, L Ngo, MH Tan, M Tao. Comparative Analysis of Extra-nodal NK/T Cell Lymphoma and Peripheral T Cell Lymphoma: Significant Differences in Clinical Characteristics and Prognosis. European Journal of Haematology 2008;80:55-60. 8. ST Lim, SW Hee, LC Lim, R Quek, D Lim, SP Yap, S Loong, I Sng, M Tao. Performance status is the single, most important prognostic factor in lymphoma patients aged greater than 75, overriding other prognostic factors such as histology. Leuk Lymphoma. 2008;49:149-51. 9. L Ngo, SW Hee, LC Lim, M Tao, R Quek, SP Yap, LE Loong, I Sng, L Tan, MK Ang, J Ngeow, MH Tan, CK Tham, ST Lim. Prognostic Factors in Patients with Diffuse Large B Cell Lymphoma: Before and After the Introduction of Rituximab. Leuk Lymphoma. 2008 Mar;49(3):462-9. 10. Kian TC, M Tao, R Quek, Peng YS, Li LE, Ivy S, Hwan-Cheong TL, Hua LH, Thye LS. Clinical characteristics, prognostic factors and outcomes of Burkitt lymphoma in adult Asians. Leuk Lymphoma. 2008; 49(4): 824-7. 11. Ang MK, Hee SW, Quek R, Yap SP, Loong S, Tan L, Tao M, Lim ST. Presence of a highgrade component in gastric mucosa-associated lymphoid tissue (MALT) lymphoma is not associated with an adverse prognosis. Ann Hematol. 2009;88(5):417-24.
4 | Page
Curriculum Vitae of Richard Quek Hong Hui
12. R Quek, JA Morgan, S George, J Butrynski, K Polson, F Meyer, GD Demetri, SD Block. Small Molecule Tyrosine Kinase Inhibitor and Depression. J Clin Oncol. 2009 Jan 10;27(2):312-3. 13. R Quek, S George. Clinical Overview of GIST. Hematol Oncol Clin North Am. 2009 Feb;23(1):69-78, viii. 14. Koo YX, Tan SW, Tan BH, Quek R, Tao M, Lim ST. Risk of Hepatitis B Virus Reactivation in Patients Who Are Hepatitis B Surface Antigen Negative/Antibody to Hepatitis B Core Antigen Positive and the Role of Routine Antiviral Prophylaxis. J Clin Oncol. 2009;27(15):2570-1. 15. Lai GG, Lim ST, Tao M, Chan A, Li H, Quek R. Late-onset neutropenia following RCHOP chemotherapy in diffuse large B-cell lymphoma. Am J Hematol. 2009;84(7):414-7. (Corresponding author) 16. Koo YX, Tan Daniel SW, Tan Iain BH, Quek R, Tao Miriam, Lim Soon Thye. “Anti-HBc alone” in human immunodeficiency virus-positive and immuno-suppressed lymphoma patients. World J Gastroenterol. 2009;15(30):3834-5. 17. Tan IB, Padhy AK, Thng CH, Osmany S, Magsombol B, Ho YH, Tham CK, Quek R, Tao M, Lim ST. Intensely hypermetabolic extra-axial brainstem tumor in erdheim-chester disease. Clin Nucl Med. 2009;34(9):604-7. 18. Chew V, Tow C, Teo M, Wong HL, Chan J, Gehring A, Loh M, Bolze A, Quek R, Lee VK, Lee KH, Abastado JP, Toh HC, Nardin A. Inflammatory tumor microenvironment is associated with superior survival in hepatocellular carcinoma patients. J Hepatol. 2010;52(3):370-379. 19. Leong C, Ngeow J, Tan I, Quek R, Tao M, Loh Y, Tan HC, Lim ST. Second hematologic malignancies after ABVD: Two case reports and a retrospective study of 183 Hodgkin lymphoma patients. Acta Oncol. 2010;49(2):257-9. 20. Quek R, George S. Update on the treatment of gastrointestinal stromal tumors (GISTs): role of imatinib. Biologics. 2010;4:19-31. 21. Morgan JA, Quek R, George S, Block SD, Demetri GD. Reply to W.F. Pirl et al. J Clin Oncol. 2009 Aug 10;27(23):e49-50. 22. Ngeow J, Tan IB, Kanesvaran R, Tan HC, Tao M, Quek R, Lim ST. Prognostic impact of bleomycin-induced pneumonitis on the outcome of Hodgkin's lymphoma. Ann Hematol. 2011;90(1):67-72. 23. Tay K, Tai D, Tao M, Quek R, Ha TC, Lim ST. Relevance of the International Prognostic Index in the rituximab era. J Clin Oncol. 2011;29(1):e14 24. Quek RH, Wang Q, Morgan JA, Shapiro GI, Butrynski JE, Ramaiya N, Huftalen T, Jederlinic N, Manola J, Wagner AJ, Demetri GD, George S. Combination mTOR and IGF-1R inhibition: Phase I trial of everolimus and figitumumab in patients with advanced sarcomas and other solid tumors. Clin Cancer Res. 2011;17(4):871-9 5 | Page
Curriculum Vitae of Richard Quek Hong Hui
25. Tang T, Tay K, Quek R, Tao M, Tan SY, Tan L, Lim ST. Peripheral T-cell lymphoma: review and updates of current management strategies. Adv Hematol. 2010;2010:624040. 26. Tai WM, Quah D, Peng Yap S, Huey Tan S, Tang T, Tay KW, Koo YX, Tao M, Quek R, Lim ST. Primary mediastinal large B-cell lymphoma: optimal therapy and prognostic factors in 41 consecutive Asian patients. Leuk Lymphoma. 2011;52(4):604-12. 27. Chan A, Leng XZ, Chiang JYL, Tao M, Quek R, Tay K, Lim ST. Comparison of daily filgrastim and pegfilgrastim to prevent febrile neutropenia in Asian lymphoma patients. Asia Pac J Clin Oncol. 2011;7(1):75-81 28. Koo YX, Tan DS, Tan IB, Tai DW, Ha T, Ong WS, Quek R, Tao M, Lim ST. Effect of concomitant statin, metformin, or aspirin on rituximab treatment for diffuse large B-cell lymphoma. Leuk Lymphoma. 2011 Aug;52(8):1509-16 29. Chiang J, Chan A, Lian T, Tay K, Quek R, Tao M, Lim ST. Management of tumor lysis syndrome with a single fixed dose of rasburicase in Asian lymphoma patients: a case series and literature review. Asia Pac J Clin Oncol. 2011 Dec;7(4):351-6 30. Chan A, Tang T, Ng T, Shih V, Tay K, Tao M, Quek R, Lim ST. To SMILE or Not: Supportive Care Matters. J Clin Oncol. 2012 Mar 20;30(9):1015-6 31. Koo YX, Tay M, Teh YE, Teng D, Tan DS, Tan IB, Tai DW, Quek R, Tao M, Lim ST. Risk of hepatitis B virus (HBV) reactivation in hepatitis B surface antigen negative/hepatitis B core antibody positive patients receiving rituximab-containing combination chemotherapy without routine antiviral prophylaxis. Ann Hematol. 2011 Oct;90(10):1219-23 32. Raut CP, Boucher Y, Duda DG, Morgan JA, Quek R, Ancukiewicz M, Lahdenranta J, Eder JP, Demetri GD, Jain RK. Effects of Sorafenib on Intra-Tumoral Interstitial Fluid Pressure and Circulating Biomarkers in Patients with Refractory Sarcomas (NCI Protocol 6948). PLoS One. 2012;7(2):e26331. Epub 2012 Feb 7 33. Koo GC, Tan SY, Tang T, Poon SL, Allen GE, Tan L, Chong SC, Ong WS, Tay K, Tao M, Quek R, Loong S, Yeoh KW, Yap SP, Lee KA, Lim LC, Tan D, Goh C, Cutcutache I, Yu W, Young Ng CC, Rajasegaran V, Heng HL, Gan A, Ong CK, Rozen S, Tan P, Teh BT, Lim ST. Janus Kinase 3-Activating Mutations Identified in Natural Killer/T-cell Lymphoma. Cancer Discov. 2012;2(7):591-597. 34. Chan A, Shih V, Chiang J, Chew L, Tay K, Quek R, Tao M, Lim ST. Clinical pharmacy services and research for lymphoma patients at a cancer center. J Oncol Pharm Pract. 2012 Jun 15. 35. Farid M, Ong WS, Tan MH, Foo LS, Lim YK, Chia WK, Soh LT, Poon D, Lee MJ, Ho ZC, Jeevan R, Chin F, Teo M, Quek R. The Influence of Primary Site on Outcomes in Leiomyosarcoma: A Review of Clinicopathologic Differences Between Uterine and Extrauterine Disease. Am J Clin Oncol. 2013 Aug;36(4):368-74 (Corresponding author)
6 | Page
Curriculum Vitae of Richard Quek Hong Hui
36. Tan PS, Koh E, Pang C, Ong WS, Ngo L, Soh LT, Quek R, Chay WY, Ho TH, Tay SK, Chew SH, Lim-Tan SK, Khoo-Tan H, Lim SL, Busmanis I, Goh LK, Chia YN, Chia WK, Lim T. Uterine Leiomyosarcoma in Asian Patients: Validation of the Revised Federation of Gynecology and Obstetrics Staging System and Identification of Prognostic Classifiers. Oncologist. 2012;17(10):1286-93. 37. M Farid, MJF Lee, MH Chew, WS Ong, A Sairi, KF Foo, SP Choo, WH Koo, S Ong, PK Koh, R Quek. Localized gastrointestinal stromal tumor of the rectum: An uncommon primary site with prominent disease and treatment-related morbidities. Molecular and clinical oncology. 2013;1:190-194. (Corresponding author) 38. Tay MR, Lim ST, Tao M, Quek RH, Tay K, Tan TT. Cytomegalovirus infection and endorgan disease in Asian patients with lymphoma receiving chemotherapy. Leuk Lymphoma. 2014 Jan;55(1):182-7 39. Chua C, Raaj J, Pan S, Farid M, Lee JF, Ho ZC, Sairi A, Sittampalam K, Tao M, Tay K, Lim ST, Chin F, Teo M, Quek R. Brain metastasis in sarcoma: Does metastasectomy or aggressive multi-disciplinary treatment improve survival outcomes. Asia Pac J Clin Oncol. 2013 Aug 13. (Corresponding author) 40. Farid M, Ong WS, Lee MJ, Jeevan R, Ho ZC, Sairi AN, Soh LT, Poon D, Teh J, Chin F, Teo M, Quek R. Cutaneous versus Non-Cutaneous Angiosarcoma: Clinicopathologic features and treatment outcomes in 60 patients at a single Asian cancer centre. Oncology. 2013 Aug 31;85(3):182-190. (Corresponding author) 41. Ngan R, Wang E, Porter D, Desai J, Prayogo N, Devi B, Quek R. Soft-tissue sarcomas in the Asia-Pacific region: a systematic review. Asian Pac J Cancer Prev. 2013;14(11):6821-32. (Corresponding author) 42. George S, Feng Y, Manola J, Nucci MR, Butrynski JE, Morgan JA, Ramaiya N, Quek R, Penson RT, Wagner AJ, Harmon D, Demetri GD, Krasner C. Phase 2 trial of aromatase inhibition with letrozole in patients with uterine leiomyosarcomas expressing estrogen and/or progesterone receptors. Cancer. 2014 Mar 1;120(5):738-43. 43.
Lewin J, Puri A, Quek R, Ngan R, Alcasabas AP, Wood D, Thomas D. Management of sarcoma in the Asia-Pacific region: resource-stratified guidelines. Lancet Oncol. 2013 Nov;14(12):e562-70.
44.
Tay MR, Lim ST, Tao M, Quek R, Tay K, Tan TT. Cytomegalovirus infection and endorgan disease in Asian patients with lymphoma receiving chemotherapy. Leuk Lymphoma. 2014 Jan;55(1):182-7
45.
Tan GL, Takano A, Cheah FK, Quek R, Koh MS. A 58-year-old Woman with Dry Cough and Pulmonary Nodules. Ann Acad Med Singapore. 2014 Jan;43(1):59-61
46. Lee JO, Tan SY, Tan LH, Lee HY, Chuah KL, Tang T, Quek R, Tay K, Tao M, Lim ST, Farid M. One Patient, Two Uncommon B-Cell Neoplasms: Solitary Plasmacytoma following Complete Remission from Intravascular Large B-Cell Lymphoma Involving Central Nervous System . Case Rep Med. 2014:620423
7 | Page
Curriculum Vitae of Richard Quek Hong Hui
47. See M, Shih V, Ho HK, Tang T, Farid M, Quek R, Tao M, Lim ST, Chan A (2014) A Pilot Study to Evaluate the Role of Therapeutic Drug Monitoring of Pegfilgrastim in Lymphoma Patients Receiving Chemotherapy. Proceedings of Singapore Healthcare. 23(1):13-20. 48. Chan A, Lim E, Ng T, Shih V, Quek R, Cheung YT. Symptom burden and medication use in adult sarcoma patients. Support Care Cancer. 2015 Jun;23(6):1709-17 49. Chok AY, Goh BK, Koh YX, Lye WK, Allen JC Jr, Quek R, Teo MC, Chow PK, Ong HS, Chung AY, Wong WK. Validation of the MSKCC Gastrointestinal Stromal Tumor Nomogram and Comparison with Other Prognostication Systems: Single-Institution Experience with 289 Patients. Ann Surg Oncol. 2015 Feb 5. [Epub ahead of print] 50. Quek R. Tumour vascular-disrupting agents in soft-tissue sarcoma. Lancet Oncol. 2015;16(5):480-1 51. Tan GH, Wong JS, Quek R, Goh BK, Kwok LL, Pan S, Soo KC, Teo MC. Role of upfront surgery for recurrent gastrointestinal stromal tumours. ANZ J Surg. 2015 Jul 14. doi: 10.1111/ans.13220. [Epub ahead of print] 52. Huang KK, McPherson JR, Tay ST, Das K, Tan IB, Ng CC, Chia NY, Zhang SL, Myint SS, Hu L, Rajasegaran V, Huang D, Loh JL, Gan A, Sairi AN, Sam XX, Dominguez LT, Lee M, Soo KC, Ooi LL, Ong HS, Chung A, Chow PK, Wong WK, Selvarajan S, Ong CK, Lim KH, Nandi T, Rozen S, Teh BT, Quek R, Tan P. SETD2 histone modifier loss in aggressive GI stromal tumours. Gut. 2015 Sep 3. pii: gutjnl-2015-309482. doi: 10.1136/gutjnl-2015309482. [Epub ahead of print] (co-corresponding author) 53. Goh BK, Chok AY, Allen JC Jr, Quek R, Teo MC, Chow PK, Chung AY, Ong HS, Wong WK. Blood neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios are independent prognostic factors for surgically resected gastrointestinal stromal tumors. Surgery. 2016 Apr;159(4):1146-56. 54. Tang T, Chen Z, Praditsuktavorn P, Khoo LP, Ruan J, Lim ST, Tan D, Phipps C, Lee YS, Goh YT, Hwang W, Tao M, Quek R, Farid M, Furman RR, Leonard JP, Martin P. Role of Surveillance Imaging in Patients With Peripheral T-Cell Lymphoma. Clin Lymphoma Myeloma Leuk. 2016 Mar;16(3):117-21. 55. Wang XJ, Tang T, Farid M, Quek R, Tao M, Lim ST, Wee HL, Chan A. Routine Primary Prophylaxis for Febrile Neutropenia with Biosimilar Granulocyte Colony-Stimulating Factor (Nivestim) or Pegfilgrastim Is Cost Effective in Non-Hodgkin Lymphoma Patients undergoing Curative-Intent R-CHOP Chemotherapy. PLoS One. 2016 Feb 12;11(2):e0148901. 56. Wong JS, Tan GH, Quek R, Goh BK, Kwok LL, Kumar M, Soo KC, Teo MC. Is multivisceral resection in locally advanced gastrointestinal stromal tumours an acceptable strategy? ANZ J Surg. 2016 May 25. doi: 10.1111/ans.13518. [Epub ahead of print] 57. Li Z, Xia Y, Feng LN, Chen JR, Li HM, Cui J, Cai QQ, Sim KS, Nairismägi ML, Laurensia Y, Meah WY, Liu WS, Guo YM, Chen LZ, Feng QS, Pang CP, Chen LJ, Chew SH, Ebstein RP, 8 | Page
Curriculum Vitae of Richard Quek Hong Hui
Foo JN, Liu J, Ha J, Khoo LP, Chin ST, Zeng YX, Aung T, Chowbay B, Diong CP, Zhang F, Liu YH, Tang T, Tao M, Quek R, Mohamad F, Tan SY, Teh BT, Ng SB, Chng WJ, Ong CK, Okada Y, Raychaudhuri S, Lim ST, Tan W, Peng RJ, Khor CC, Bei JX. Genetic risk of extranodal natural killer T-cell lymphoma: a genome-wide association study. Lancet Oncol. 2016 Jul 25. pii: S1470-2045(16)30148-6. doi: 10.1016/S1470-2045(16)30148-6. [Epub ahead of print] (A) Refereed Journals As listed above.
(B) Non-refereed publications Non-refereed publications refer to those which do not routinely use a system of critical review prior to publication; such articles are often solicited by the publisher. (i) Reviews Articles NA
(ii)
Books & Chapters 1. Richard Quek, George Demetri and Suzanne George. Chapter IV Soft Tissue Sarcoma. In: Straus DJ and Varadhachary G, eds. Castle Connolly Graduate Board Review Series: Educational Review Manual in Medical Oncology. 8th Edition. 2. Richard Quek and Suzanne George. Smooth Muscle Tumors – Leiomyosarcoma. In: CP Raut
ed. Sarcoma: Diagnosis and Management. Springer (In press).
(iii)
Selected abstracts (Optional) 1. Malignant Lymphomas and Hepatitis B Virus Infection: An Epidemiological and Clinicopathological study. Lim ST, Quek R, Gao Lim ST, Lim LC, Lee LH, Yap SP, Loong S, Tao M. European Society of Medical Oncology Meeting 2006, Istanbul, Turkey, P 657. 2. FOXO3a predicts for survival and its phosphorylated form is downregulated following mTOR or MEK inhibitor therapy in Hepatocellular Carcinoma. Teo M, Huynh HT, Hee SW, Phoon YP, Quek R, Wang P, Toh HC. American Society of Clinical Oncology 2007. 3. Increased foxp3+ regulatory T cells predicts for superior relapse-free and overall survival in early stage Hepatocellular Carcinoma. Toh HC, Phoon Y P, Quek R, Banham AH, Tan SY. American Society of Clinical Oncology 2007. 4. MALT lymphomas show different behavior and clinical outcomes depending on their primary location. Ang MK, Tao M, Quek R, Sng I, L Tan, Lim ST. Lancet Asia Medical Forum 2007.
9 | Page
Curriculum Vitae of Richard Quek Hong Hui
5. Burkitt’s lymphoma: Favorable outcome among patients treated aggressively in an Asian institution. Tham CK, Tao M, Quek R, Lim LC, Sng I, Li HH, Lim ST. Lancet Asia Medical Forum 2007. 6. Utility of whole body positron emission tomography in detection of lymphomatous bone marrow involvement – our local experience. Ngeow JYY, Quek R, Ng DCE, Tao M, Lim ST. Lancet Asia Medical Forum 2007. 7. High-dose therapy and autologous hematopoietic stem cell transplantation (AHSCT) for relapsed or intermediate and high risk aggressive Non-Hodgkin’s lymphoma in the Department of Medical Oncology, National Cancer Centre. Quek R, Lim ST, Hee SW, Gao YJ, Teo CP, Tao M. AACR Centennial Conference on Translational Cancer Medicine 2007: Abstract 25 8. Upfront Lamivudine Prophylaxis is Superior to a Selective Treatment Strategy in Hepatitis B carriers receiving Anthracycline-based Chemotherapy in the Pre- and Post-Rituximab Era. Tan DSW, Tan IB, Quek R, Tao M, Lim ST. 33rd European Society of Medical Oncology (ESMO) 2008. 9. Geriatric high-grade soft tissue sarcoma (G-HG STS): An analysis of 116 patients (pts) evaluating prognostic factors and clinical outcomes stratified by histology. R Quek, M Farid, S Pan, MH Tan, LSS Foo, K Sittampalam, A Sairi, K Adam, W Hanafi, ST Lim, K Tay, LT Soh, F Chin, M Teo, D Poon. ASCO Meeting Abstracts May 30, 2012:10051 10. Liposarcoma (LPS): Influence of primary tumour site and histology sub-type on clinical outcomes. SL Koo, A. Sairi, S Pan, L Foo, MH Tan, F Chin, K Sittampalam, M Teo, M Farid, R Quek. European Society of Medical Oncology Meeting Abstracts 2012 11. Undifferentiated pleomorphic sarcoma (UPS): An analysis of 135 patients (pts) with this clinically unique subtype of high-grade soft-tissue sarcoma (HG-STS). MF Harunal Rashid, S Pan, MH Tan, LSS Foo, K Sittampalam, A Sairi, K Adam, F Chin, M Teo, R Quek. European Society of Medical Oncology Meeting Abstracts 2012 12. Clinical outcomes and prognostic factors in adult patients with synovial sarcoma. A. Sairi, K. Wong, C. Lim, L. Foo, M.H. Tan, J.Y.H Teh, S. Selvarajan, M. Teo, M. Farid, R. Quek. Australian Sarcoma Group Annual Meeting 2012 13. Is advanced age and adverse prgonostic factor in localised high grade soft tissue sarcoma (STS)? Natalie, Cindy, Alisa, Melissa Teo, Jonathan Teh, Francis Chin, Sathiya, Kesavan, Tan Mann Hong, Tiffany Tang, Miriam Tao, Lim Soon Thye, Farid, Richard Quek. Connective Tissue Oncology Society Annual Meeting 2013 14. Head and neck primary site is an independent adverse prgonostic factor in localised soft tissue sarcomas (STS). Alisa, Summer, Melissa Teo, Gopal, Jonathan Teh, Francis Chin, Sathiya, Kesavan, Tan Mann Hong, Tiffany Tang, Miriam Tao, Lim Soon Thye, Soo Khee Chee, Richard Quek, Farid. Connective Tissue Oncology Society Annual Meeting 2013
10 | P a g e
Curriculum Vitae of Richard Quek Hong Hui
15. Nagavalli Somasundaram, Rebecca Lim, Jermain Chng, Dan Liang Ho, Anna Gan, Clarinda Wei Ling Chua, Mohamad Farid, Sarah B Ng, Iain B. Tan, Richard Hong Hui Quek. An NGS assay strategy with FFPE and cfDNA to determine primary and secondary mutations across the initial diagnosis and subsequent recurrence/progression of patients with localized, recurrent and metastatic GIST. J Clin Oncol 33, 2015 (suppl; abstr 10519)
(C) Top 10 publications (Optional for Assistant Professor candidates) Ranking Order 1
Publication Title of Article Year 2015 Huang KK, McPherson JR, Tay ST, Das K, Tan IB, Ng CC, Chia NY, Zhang SL, Myint SS, Hu L, Rajasegaran V, Huang D, Loh JL, Gan A, Sairi AN, Sam XX, Dominguez LT, Lee M, Soo KC, Ooi LL, Ong HS, Chung A, Chow PK, Wong WK, Selvarajan S, Ong CK, Lim KH, Nandi T, Rozen S, Teh BT, Quek R, Tan P.
Type of Journal/ Publication Oncology/ research
Name of publication Gut
SETD2 histone modifier loss in aggressive GI stromal tumours. 2
2011
Quek RH, Wang Q, Morgan JA, Shapiro GI, Butrynski JE, Ramaiya N, Huftalen T, Jederlinic N, Manola J, Wagner AJ, Demetri GD, George S. Combination mTOR and IGF-1R inhibition: Phase I trial of everolimus and figitumumab in patients with advanced sarcomas and other solid tumors.
Oncology
Clinical Cancer Research
3
2009
R Quek, JA Morgan, S George, J Butrynski, K Polson, F Meyer, GD Demetri, SD Block. Small Molecule Tyrosine Kinase Inhibitor and Depression.
Oncology
Journal of Clinical Oncology
4
2013
George S, Feng Y, Manola J, Nucci MR, Butrynski JE, Morgan JA, Ramaiya N, Quek R, Penson RT, Wagner AJ, Harmon D, Demetri GD, Krasner C. Phase 2 trial of aromatase inhibition with
Oncology
Cancer
11 | P a g e
Curriculum Vitae of Richard Quek Hong Hui
letrozole in patients with uterine leiomyosarcomas expressing estrogen and/or progesterone receptors. 5
2013
Lewin J, Puri A, Quek R, Ngan R, Alcasabas AP, Wood D, Thomas D. Management of sarcoma in the Asia-Pacific region: resourcestratified guidelines.
Oncology
Lancet Oncology
6
2012
Tan PS, Koh E, Pang C, Ong WS, Ngo L, Soh LT, Quek R, Chay WY, Ho TH, Tay SK, Chew SH, Lim-Tan SK, Khoo-Tan H, Lim SL, Busmanis I, Goh LK, Chia YN, Chia WK, Lim T. Uterine Leiomyosarcoma in Asian Patients: Validation of the Revised Federation of Gynecology and Obstetrics Staging System and Identification of Prognostic Classifiers
Oncology
Oncologist
7
2013
Ngan R, Wang E, Porter D, Desai J, Prayogo N, Devi B, Quek R. Soft-tissue sarcomas in the AsiaPacific region: a systematic review.
Oncology
Asian Pacific Journal Cancer
8
2013
Farid M, Ong WS, Tan MH, Foo LS, Lim YK, Chia WK, Soh LT, Poon D, Lee MJ, Ho ZC, Jeevan R, Chin F, Teo M, Quek R. The Influence of Primary Site on Outcomes in Leiomyosarcoma: A Review of Clinicopathologic Differences Between Uterine and Extrauterine Disease
Oncology
American Journal of Clinical Oncology
9
2009
R Quek, S George. Clinical Overview of GIST.
Oncology
Hematol Oncol Clin North Am
(D) h-index NA
12 | P a g e
Curriculum Vitae of Richard Quek Hong Hui
(9) Intellectual Property (A) Total number of Duke-NUS affiliated Invention Disclosures submitted : 0
(B) Total number of Duke-NUS affiliated Trademarks submitted
: 0
(C) Total number of Duke-NUS affiliated Patents filed : 0
Inclusive of provisional and published patents. (D) Total number of Duke-NUS affiliated IP granted / registered : 0
Inclusive of copyrights and trademarks registered.
(E) Duke-NUS Patents published
13 | P a g e
Curriculum Vitae of Richard Quek Hong Hui
Publication Publication Date Number
Title
Inventor(s)
Patent Office Coun
NA
(F) Duke-NUS Copyrights and Trademarks registered
14 | P a g e
Curriculum Vitae of Richard Quek Hong Hui
Registration Type Date
Title
Inventor(s)
Registration Number
NA
(10) Editorship Please state your role; e.g. editor, reviewer or member of editorial board. May include editorship of journals and books. NA
(11) Education Activities (Teaching Portfolio) Please include only activities related to Medical Education, or educational activities related to research. Please list the activities chronologically, beginning with the oldest first. (A)
Educational Philosophy (500 words max): Personal theory of learning A combination of multiple theories including cognitivism and behaviorism. Goals of instruction To create the appropriate learning environment and stimulate interest in students with aims to promote life-long self-learning. Role and responsibility of study and instructor Distinct complementary roles for both the student and instructor to enhance the learning process. The instructor must set and communicate the goals of learning, assess and give feedback to the learner. The learner in turn should receive and process this learning, selfdirect the learning process with a view to engage in self-learning Variables that promote learning Many variables promote learning. These include but are not limited to clear program goals, student characteristics including self-motivation, enthusiasm and attitudes, classroom instruction including topic presentation, organization and time management, out of school support including self and peer-directed learning and overall school organization
(B) Seminars/ Lectureships (i) Local 1. Organizing Chairman and speaker for 1st Singapore Sarcoma Consortium Research and Education Meeting 2013 2. Organizing Chairman and speaker for 2nd Singapore Sarcoma Consortium Research and Education Meeting 2014 3. Oncological treatment of advanced melanomas. Dermatological Society of Singapore Annual Scientific Meeting 2014 15 | P a g e
Curriculum Vitae of Richard Quek Hong Hui
Coun
4. Organizing Chairman and speaker for 3rd Singapore Sarcoma Consortium Research and
Education Meeting 2015
(ii) International 1. Association for Medical education Europe (AMEE) 2013 conference 2. Essential Skills in Medical Education (ESME) Course 2013 3. Harvard Macy Institute Program for Educators in Health Professions. Jan 10-20 and May 16-20 2016 (C) Teaching Activities in local institutions (Optional for PhD Research Investigators) (i) Undergraduate education: Per departmental education plan (ii) Postgraduate education: Program Director SingHealth / National Cancer Centre Singapore Medical Oncology Residency Program (D) Leadership positions / roles in Education (e.g. Course Directorship, Curriculum Planning / Development Committees etc.) Please include the title, date/period, audience, a brief description and frequency conducted.
Program Director SingHealth / National Cancer Centre Singapore Medical Oncology Residency Program (E) Advisory/Mentoring Role: Please include date (range from- to), Student Name, Student level (med student, fellow, Post Grad , faculty , resident), Title of Student work.
Date Jun 2010 – Apr 2012
Student Marcus Lee Jin Fu
Student Level Medical student
Oct 2010 – Feb 2012
R. Jeevan
Medical student
Oct 2010 – Mar 2012
Ho Zhong Chen
Medical student
Title of Student’s Work Abstracts M Farid, WS Ong, MH Tan, LS Foo, YK Lim, WK Chia, LT Soh, D Poon, MJ Lee, ZC Ho, R Jeevan, F Chin, M Teo, R Quek. The influence of primary site on outcomes in Leiomyosarcoma: A review of Clinicopathologic differences between uterine and extrauterine disease. Am J Clin Oncol. 2012 Jul 3 [Epub ahead of print] R.H. Quek, M Farid, WS Ong, MJF Lee, R Jeevan, ZC Ho, F Chin, LT Soh, D Poon, M Teo. Mucocutaneous
16 | P a g e
Curriculum Vitae of Richard Quek Hong Hui
angiosarcoma (MC-AS) vs non MCAS: Clinicopathologic features and treatment outcomes in 44 patients (pts). American Society of Clinical Oncology Meeting Abstracts Jun 9, 2011:10091 C Chua, R Jeevan, M Farid, MJF Lee, ZC Ho, FL Leong, A Sairi, F Chin, M Teo, R Quek. Brain metastasis in sarcoma: Presentation, treatment strategies and survival in this rare clinical setting. European Multidisciplinary Cancer Congress Meeting Abstracts 2011 Sep 2011 – Jun 2012
Kiraely Adam Wong Zhongren
Poly Intern
Abstracts / Posters K. Adam, A Sairi, M. Farid, S. Pan, H. Widayana, A. Manaf, L. Soh, R. Quek. Trabectedin in Sarcoma: Initial Experience in The Asian Setting. Asian Oncology Summit 2012 K. Adam, M. Farid, A Sairi, S. Pan, H. Widayana, A. Manaf , L. Soh, R. Quek. Efficacy and safety of trabectedin versus gemcitabine/docetaxel in patients with sarcoma after failure of anthracycline and/or ifosfamide. Asian Oncology Summit 2012 A Sairi, K Wong, C Lim, L Foo, MH Tan, JYH Teh, S Selvarajan, M Teo, M Farid, R Quek. Clinical outcomes and prognostic factors in adult patients with synovial sarcoma (SS). Australian Sarcoma Group Annual Meeting 2012 Abstracts R Quek, M Farid, S Pan, MH Tan, LSS Foo, K Sittampalam, A Sairi, K Adam, W Hanafi, ST Lim, K Tay, LT Soh, F Chin, M Teo, D Poon. Geriatric highgrade soft tissue sarcoma (G-HG STS): An analysis of 116 patients (pts) evaluating prognostic factors and clinical outcomes stratified by histology. American Society of Clinical
17 | P a g e
Curriculum Vitae of Richard Quek Hong Hui
Oncology Meeting Abstracts May 30, 2012:10051
Sep 2012 – Feb 2013
Soh Keng Keat Gilbert
Medical Student
MF Harunal Rashid, S Pan, MH Tan, LSS Foo, K Sittampalam, A Sairi, K Adam, F Chin, M Teo, R Quek. Undifferentiated pleomorphic sarcoma (UPS): An analysis of 135 patients (pts) with this clinically unique subtype of high-grade soft-tissue sarcoma (HGSTS). European Society of Medical Oncology Meeting Abstracts 2012 Contributed in Sarcoma/Melanoma: Epidemiology, Diagnoses and Clinical Outcomes from a Large Single Asian Comprehensive Cancer Centre
(F) Educational Administration: Please include the period of engagement, organization and your title / role.
1 Jul 2012 – Present: Program Director for SingHealth / National Cancer Centre Singapore Medical Oncology Residency Program
(G) Continuing Medical Education (date, title, certificate): Please provide the date, title and certificate. Describe how you have implemented the lesson to improve your own teaching.
• • • • •
Attended the necessary yearly CME programs per SMC requirements Attendance and participation in departmental journal clubs and teaching sessions Organized and lectured in medical oncology residency program Lectured at local and regional sarcoma and gastrointestinal stromal (GIST) conferences Attendance and participation in international cancer conferences
(12) Clinical Activities NA
(13) Courses / Conferences Attended and Speaking Invitations Please list chronologically, beginning with the oldest first. (A) With presentations
18 | P a g e
Curriculum Vitae of Richard Quek Hong Hui
1. Clinico-pathological Study of Malignant Lymphoma in a Large Cohort of Asian Patients: Clinical and Research Implications. 41st Singapore Malaysian Congress of Medicine. 20th July 2007 2. Molecular Aspects of Gastrointestinal Stromal Tumors (GIST). Asian Oncology Summit 2010. 10th April 2010 3. Molecular Aspects of Gastrointestinal Stromal Tumors (GIST). Asian Oncology Summit 2010. April 10, 2010 4. Phase I clinical trial of everolimus (RAD001) in combination with CP-751, 871 in patients (pts) with advanced sarcomas and other malignant neoplasms. American Society of Clinical Oncology (ASCO) Annual Meeting 2010. 7th June 2010. 5. Systemic Chemotherapy in Soft Tissue Sarcoma. Hong Kong. Jul 26-27, 2010 6. Australian Sarcoma Group 2010 Annual Scientific Meeting. Tailoring Sarcoma management in 2010. Sydney, Australia. Oct 16-17, 2010. 7. Soft Tissue Sarcoma: A Tailored and Targeted Management Approach in the Modern Era. Hong Kong. Jan 18-23, 2011. 8. Latest development in the management of STS. Thailand. May 21, 2011. 9. New treatment option for STS: Yondelis. Thailand. May 21, 2011. 10. Australian Sarcoma Group 2012 Annual Scientific Meeting. The challenges and achievements of sarcoma care in Singapore and opportunities for collaboration with the ASSG. Australia. Oct 13-14, 2012. 11. College of Radiology, Academy of Medicine of Malaysia Annual Scientific Meeting 2013. Management of Ewing’s Sarcoma. Jun 14, 2013 12. College of Radiology, Academy of Medicine of Malaysia Annual Scientific Meeting 2013. Soft Tissue Sarcoma: Management of Advanced Disease. Jun 15, 2013 13. 2nd Singapore Sarcoma Consortium Education and Research Meeting 2014. Management of Advanced Gastrointestinal Stromal Tumor (GIST). 26 Apr 2014 14. 2nd Singapore Sarcoma Consortium Education and Research Meeting 2014. Current landscape of systemic chemotherapy in soft tissue sarcoma26 Apr 2014 15. Hanoi Oncology Conference. Advances in the adjuvant treatment of GIST. Oct 17, 2014 16. Beijing International Melanoma Conference. Management of melanoma and kidney cancer in Singapore. Oct 19, 2014 17. INSEAD Asian International Executive Program. 26 Oct – 6 Nov 2015 18. ESMO-Asia 2015. What is the treatment of a sarcoma arising in a teratoma? Dec 19, 2015 19 | P a g e
Curriculum Vitae of Richard Quek Hong Hui
19. ESMO-Asia 2015. How does biology guide the treatment of sarcoma? (Soft tissue sarcoma). Dec 21, 2015 (B) Without presentations (Optional for PhD Research Investigators) Conferences attended (without abstract/poster/presentation).
European Society of Medical Oncology 2010 8th World Congress of Melanoma 2013
(14) Research Activities (A) Research Funding Support Role Project Title (e.g. P.I., Co-I., etc.) PI Sarcoma: Epidemiology, Diagnoses and Clinical Outcomes from a Large Single Asian Comprehensive Cancer Centre PI Molecular Studies in Gastrointestinal Stromal Tumor (GIST) PI Analysis of molecular alterations in gastrointestinal stromal tumour (GIST) using immunohistochemistry, gene sequencing and expression profiling Co-I Overcoming drug resistance in cancer targeted therapy by combining genomics and molecular studies PI Phase II clinical study of metronomic oral cyclophosphamide in elderly and/or pretreated patients with advanced sarcomas
Currency/ Amount
Project Start date
$82,999.00
2007
Duration
2010 $70,000.00
2010
0.2FTE
1 Dec 2010
$30,000
13 Jan 2012
4 years
(B) Collaboration with Local and Overseas Institution Please state if the project is completed or ongoing.
Principal investigator (Singapore) International investigator-initiated trial with the Australian Sarcoma Study Group A stratified multi-arm Phase 2 study evaluating the efficacy and safety of LDE225 in patients with advanced/metastatic sarcoma (C) Research Interests Dr Quek’s chief research interest is primarily focused on translational therapeutics, developing new molecularly targeted therapeutics in both sarcoma and lymphoma in an academic environment. The two years he spent at the Center for Sarcoma and Bone Oncology in Dana-Farber Cancer Institute (DFCI) under the close supervision of Dr George Demetri and Dr Suzanne George prepared him well for this area of research. During this time he 20 | P a g e
Curriculum Vitae of Richard Quek Hong Hui
participated in the conduct of investigator-initiated clinical trials using novel biologically rationale agents targeting molecularly-defined subsets of sarcomas. He was primarily involved in the design, writing and execution of complex investigator-initiated phase I and II studies. And as part of these studies he worked closely with the clinical research team from DFCI sarcoma department in liaising with our drug sponsor(s), DFCI Institutional Review Board as well as U.S. FDA regulatory authorities to ensure the safety of our patients and accuracy of our studies. Additionally he was also involved in various multi-center pharmaceutical-sponsored studies that the department led and/or participated in the time he was in DFCI. Since returning to Singapore, he has led the centre’s efforts in developing our soft tissue/ bone and GIST sarcoma database, the first of its kind in Singapore. From this database the study team has submitted 2 abstracts to the upcoming annual American Society of Oncology (ASCO) 2011 meeting. Both abstracts have been accepted to this important international oncology meeting. Additionally he is serving as Principal Investigator to a phase 3 international study on GIST studying the efficacy and safety of a novel tyrosine kinase inhibitor, regorafenib, in patients with treatment-refractory GIST. Notably this is work he started while he was doing his fellowship training in USA, then working on the phase II aspect of this study which has since moved on to an international phase III study. Dr Quek is also heavily involved in preclinical research, being the Principal Investigator of three laboratory-based studies in collaboration with others looking into various molecular aspects of GIST and sarcomas.
(15) Committee Work (A) Hospital National Cancer Centre Singapore (NCCS) Joint Commission International (JCI) reaccreditation. Chairman for Care of Patient (COP) Standard (B) Ministry of Health NA (C) University / Medical School NA (D) Professional Bodies Chapter of Medical Oncology Secretary 2011 to 2013 Chapter of Medical Oncology Board Member 2014 - present (D) Others NA
(16) Awards & Honours (A) Academic / Clinical Awards
21 | P a g e
Curriculum Vitae of Richard Quek Hong Hui
1997
Distinction in Obstetrics and Gynaecology
1997
Dean’s List National University of Singapore
2007-2008
Human Manpower Development Plan (HMDP) Award Dana-Farber Cancer Institute. Boston Massachusetts, USA.
2008-2009
National Medical Research Council (NMRC) Research Training Fellowship Award Dana-Farber Cancer Institute. Boston Massachusetts, USA.
(B) Others 2004 2005 2013 2015
Service Excellence Award (Silver), SPRING Singapore Service Excellence Award (Gold), SPRING Singapore SingHealth Excellence Award 2013: Outstanding Educator Award (Special Mention) SingHealth Excellence Award 2015: Outstanding Educator Award
(17) Top 10 Contributions (Optional for PhD Research Investigators) Please list the contributions you are most satisfied with. Rank Describe the contribution Year of Contribution (From most satisfied onwards) Sarcoma Research Key opinion leader in Sarcoma research in Singapore, 2008 to current National Cancer Centre Singapore’s (NCCS) as well as the Asia Pacific region Program director to Medical Program Director Oncology Residency Program Teaching, mentoring and grooming the next generation of medical oncologists Departmental leadership Deputy Head of Department
2013 to current
Melanoma Research
2014 to current
Vice President Asia Melanoma Group
2013 to current
(18) Hobbies / Special Interests (Optional for PhD Research Investigators) Reading, sports, photography
22 | P a g e
Curriculum Vitae of Richard Quek Hong Hui
Note: In submitting this CV, I hereby agree to it being shared between Duke-NUS and SingHealth in association with any official matters in either or both of these institutions.
23 | P a g e
Curriculum Vitae of Richard Quek Hong Hui
